bioMerieux Launches Innovation in Motion Bus Tour
Posted on: Monday, 23 May 2005, 09:00 CDT
DURHAM, N.C., May 23 /PRNewswire/ -- Today, bioMerieux, Inc., a world leader in the field of in vitro diagnostics, launched its Innovation in Motion tour, a high-tech bus-board presentation theater and mobile laboratory. The full size luxury bus is equipped with the bioMerieux Integrated Solution, including: BacT/ ALERT(R) 3D, VITEK(R) 2 Compact and STELLARA(TM), both diagnostic and IT equipment. The purpose of the 50-city tour is to bring a demonstration of the latest diagnostic technologies to cutting-edge hospital laboratory technicians, pharmacists and physicians across the country. The Innovation in Motion Tour's goal is to demonstrate how laboratory data can be transformed into clinician advisory. The audience will include laboratory professionals, pharmacy and other key administrative roles such as risk management, hospital administrators, clinicians and practitioners.
"This is a unique effort in the diagnostics industry and will provide us the opportunity to demonstrate our technology first-hand with health care innovators across the United States," said Eric Bouvier, bioMerieux's North American president. "Our mission for the tour is to spread awareness about how the collective benefits of integrating diagnostics with clinical decision support software and other information systems can have a positive impact on improving patient care and lowering administrative costs, while streamlining the flow of diagnostic information to clinicians."
The tour begins in St. Louis, Missouri, home of bioMerieux's mid-west U.S. facilities, and the 'birthplace' of VITEK and VITEK 2, the market leading systems for identification and antibiotic susceptibility testing. The theme of the tour is Innovation in Motion, designed to illustrate rapid results, increased productivity, automated bacterial identification, extensive clinical intervention and improved safety. The focus of the tour will be to visit innovative, small to mid-sized hospitals in 50 towns and cities that may not have ready access to demonstrations of this sort. bioMerieux also plans to offer special promotions and discounts during this four-month road show. For more information, visit http://www.biomerieux-usa.com/innovation .
The Innovation in motion tour is sponsored by key alliances, Cardinal Health, Inc., Fisher Scientific Company and TheraDoc.
About bioMerieux, Inc.
bioMerieux, Inc. is the U.S. subsidiary of bioMerieux S.A., a company headquartered in France. bioMerieux is a leading international diagnostics group that specializes in the field of in vitro diagnostics for clinical and industrial applications. bioMerieux designs, develops, manufactures and markets systems (i.e. reagents, instruments and software) used in:
- Clinical applications: the diagnosis of infectious diseases such as
hepatitis, HIV, tuberculosis and respiratory illnesses, as well as
pathologies such as certain cardiovascular diseases and certain cancers,
based on the analysis of biological samples (such as blood, saliva or
urine); and
- Industrial applications: the microbiological analysis of food,
environments (such as water and air), surfaces and pharmaceutical and
cosmetic products, based on product or environmental samples.
In 2004, bioMerieux sales reached 931 million euros (i.e., approximately 1.2 billion dollars). The company is present in more than 130 countries through 33 subsidiaries and a large network of distributors, which positions the company well to benefit from the growth potential of the in vitro diagnostics market. Some important drivers that underpin this growth are aging populations and age-related illness, illnesses related to life-style and eating habits, emerging new pathogens, the development of antibiotic-resistant bacteria, the fight against bio-terrorism, the recognition of the importance of the quality of food products.
bioMerieux is listed on the Eurolist by Euronext Paris (symbol "BIM", ISIN code: FR0010096479). For more information, visit the web site at http://www.biomerieux-usa.com/ .
bioMerieux
CONTACT: Paige Sargent of French-West-Vaughan, +1-919-277-1162, orpsargent@fwv-us.com
Web site: http://www.biomerieux-usa.com/innovationhttp://www.biomerieux-usa.com/
Source: PRNewswire
Related Articles
- Roche Introduces New Automated Clinical Laboratory System for CE-Marked Testing of Human Papillomavirus, Chlamydia and N. gonorrhoeae
- Ikonisys Receives CMS Registration to Establish Clinical Laboratory for Proprietary, Rare-Cell Based Tests
- Congressman Altmire Tours Women's Health Clinical Laboratory; Learns Vital Role in Patient Care
- ExonHit and bioMerieux Amend Diagnostic Partnership
- Siemens Customers Innovate Their Clinical and Financial Workflows With Help From Soarian
- Provista Life Sciences Announces the Opening of Its Clinical Laboratory - Provista Diagnostics (PDx)
- bioMerieux, Inc. Acquires Innovative Microbial Genotyping Technology
- This Clinical Laboratory Testing Market Overview Provides the Information and Analysis You Need to Gain an Understanding of the Clinical/Diagnostic Testing Market and the Trends Which Affect It
 |
 |
User Comments (0)
RSS Feeds